Agios Pharmaceuticals (NASDAQ:AGIO) Upgraded at BidaskClub
AGIO has been the topic of a number of other research reports. Cowen restated a buy rating on shares of Agios Pharmaceuticals in a report on Friday, May 31st. Goldman Sachs Group reaffirmed a neutral rating and issued a $55.00 target price on shares of Agios Pharmaceuticals in a research report on Thursday, May 23rd. Royal Bank of Canada set a $89.00 price objective on Agios Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 2nd. BMO Capital Markets began coverage on Agios Pharmaceuticals in a research note on Thursday. They set an outperform rating and a $45.00 price objective for the company. Finally, Zacks Investment Research upgraded Agios Pharmaceuticals from a sell rating to a hold rating and set a $46.00 price objective for the company in a research note on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $68.57.
NASDAQ AGIO traded up $0.08 on Thursday, reaching $38.23. The company’s stock had a trading volume of 26,835 shares, compared to its average volume of 516,428. Agios Pharmaceuticals has a twelve month low of $33.17 and a twelve month high of $79.17. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.91 and a current ratio of 5.96. The stock has a market cap of $2.24 billion, a PE ratio of -6.35 and a beta of 2.22. The firm’s 50 day moving average is $40.88 and its two-hundred day moving average is $51.45.
Several large investors have recently added to or reduced their stakes in AGIO. NumerixS Investment Technologies Inc acquired a new position in shares of Agios Pharmaceuticals during the 2nd quarter worth approximately $35,000. US Bancorp DE increased its holdings in shares of Agios Pharmaceuticals by 82.6% in the second quarter. US Bancorp DE now owns 1,010 shares of the biopharmaceutical company’s stock worth $50,000 after buying an additional 457 shares during the period. ETF Managers Group LLC increased its holdings in shares of Agios Pharmaceuticals by 63.0% in the second quarter. ETF Managers Group LLC now owns 2,851 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 1,102 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Agios Pharmaceuticals by 27.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,666 shares of the biopharmaceutical company’s stock worth $183,000 after buying an additional 779 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its holdings in shares of Agios Pharmaceuticals by 481.6% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,280 shares of the biopharmaceutical company’s stock worth $221,000 after buying an additional 2,716 shares during the period.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.
Featured Article: What are some reasons analysts would give stocks a buy rating?
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.